All In Biotech

Drug Trial Radar · NCT04036409

Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients

A Randomized Controlled Trial to Assess the Effect of Intensive Blood Pressure Control on Major Cardiovascular Events in Stroke Patients

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 4,368 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,368

Actual

Start

Aug 5, 2019

Primary completion

Jul 8, 2026

Study completion Jul 8, 2026

Sponsor

Lead sponsor
Hospital Israelita Albert EinsteinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, Brazil
First posted
Jul 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Elevated blood pressure (BP) consists of a major public health concern especially in low and middle income countries. Besides being a highly prevalent condition, it is also a risk factor for several major cardiovascular events including stroke (which consists of the second leading cause of death in developing countries) and coronary artery disease, and is also related to cognitive decline. The OPTIMAL Stroke trial consists of a two-arm, multicenter, randomized clinical trial designed to test whether a lower target systolic blood pressure (SBP) as compared to the currently recommended target for stroke patients will reduce the occurrence of major cardiovascular events.

Conditions

  • Ischemic Stroke
  • Blood Pressure
  • Cognitive Impairment
  • Vascular Diseases

Interventions

  • Intensive Control of Systolic Blood Pressure (SBP)Drug

    Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine

  • Standard control of Systolic Blood Pressure (SBP)Drug

    The same medications used in the Intensive BP arm will be used for the Standard BP arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or hospitalization for heart failure [ Time Frame: From randomization; for approximately a mean of 3.5 years ]Time frame: From randomization; for approximately a mean of 3.5 years

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Clínica Silvestre Santé

    Rio Branco, Acre, Brazil

  • Centro de Pesquisas Clinicas (Centro Universitário Cesmac / Hospital do Coração de Alagoas)

    Maceió, Alagoas, Brazil

  • UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - FMB/UNESP

    Botucatu, Botucatu, Brazil

  • Hospital Geral de Fortaleza

    Fortaleza, Ceará, Brazil

  • Universidade Federal do Ceará / Hospital Universitário Walter Cantídio

    Fortaleza, Ceará, Brazil

  • Hospital Universitário Professor Edgard Santos

    Salvador, Estado de Bahia, Brazil

  • Hospital Ana Nery

    Salvador, Estado de Bahia, Brazil

  • Instituto Hospitalar de Base Do Distrito Federal

    Brasília, Federal District, Brazil

  • Universidade Federal de Goias

    Goiânia, Goiás, Brazil

  • Hospital Universitário Maria Aparecida Pedrossian - UFMS

    Campo Grande, Mato Grosso do Sul, Brazil

  • Flumignano Instituto de Medicina

    Curitiba, Paraná, Brazil

  • PROCAPE-Pronto Socorro Cardiológico de PE Prof. Luiz Tavares

    Recife, Pernambuco, Brazil

  • Hospital Universitário Pedro Ernesto - UERJ

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Hospital Moinho de Ventos

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Governador Celso Ramos

    Florianópolis, Santa Catarina, Brazil

  • Clínica Neurológica e Neurocirurgica de Joinville LTDA

    Joinville, Santa Catarina, Brazil

  • CMEP Centro Multidisciplinar de Ensino Especializado e Pesquisa Ltda

    Joinville, Santa Catarina, Brazil

  • Hospital Univ. São Francisco de Assis na Providencia de Deus

    Bragança Paulista, São Paulo, Brazil

  • Universidade Estadual de Campinas - Hospital de Clínicas

    Campinas, São Paulo, Brazil

  • Hospital Carlos Fernando Malzoni

    Matão, São Paulo, Brazil

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo

    Ribeirão Preto, São Paulo, Brazil

  • Clínica Vilela e Martin

    São José do Rio Preto, São Paulo, Brazil

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Hospital das Clínicas da FMUSP

    São Paulo, São Paulo, Brazil

  • Irmandade da Santa Casa de Misericórdia de São Paulo

    São Paulo, São Paulo, Brazil

  • Instituto Dante Pazzanese de Cardiologia

    São Paulo, São Paulo, Brazil

  • Hospital São Paulo

    São Paulo, São Paulo, Brazil

  • InCor - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.